Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients

Published on Jun 29, 2015in PLOS ONE2.776
· DOI :10.1371/journal.pone.0130392
Eun Ju Cho16
Estimated H-index: 16
(SNU: Seoul National University),
Jeong-Hoon Lee24
Estimated H-index: 24
(SNU: Seoul National University)
+ 8 AuthorsHyo Suk Lee43
Estimated H-index: 43
(SNU: Seoul National University)
The efficacy of entecavir (ETV) and tenofovir (TDF) for the treatment of nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients has been little studied. Here, we compare the efficacy of both ETV and TDF in NA-experienced CHB patients without detectable genotypic resistance. This retrospective cohort study included consecutive NA-experienced patients who had neither current nor previous genotypic resistance and had received ETV or TDF for at least 6 months. Overall, 202 patients (146 patients in the ETV group and 56 in the TDF group) were analyzed. The cumulative probabilities of complete virologic suppression (CVS) at month 12 were 76.1% in the ETV group and 95.0% in the TDF group (P<0.001), respectively. The TDF-treated group achieved CVS more rapidly than the ETV group for both Hepatitis B e antigen (HBeAg)-negative and -positive patients (P = 0.006 and < 0.001, respectively), and for those with both low (< 2,000 IU/mL) and high (≥ 2,000 IU/mL) HBV DNA levels (P = 0.01 and 0.002, respectively). TDF group had an increased probability of achieving CVS (hazard ratio, 2.242; 95% confidence interval, 1.587–3.165; P = 0.001), after adjustment for HBV DNA level, the presence of HBeAg, and a history of CVS during prior treatment. During the treatment period, 23 patients (15.8%) in the ETV group developed virologic breakthrough, compared to none in the TDF group. The cumulative probabilities of developing virologic breakthrough and ETV-resistance at month 24 were 9.7% and 5.3%, respectively. In conclusion, TDF is preferable to ETV for achieving CVS in NA-experienced CHB patients without genotypic resistance.
  • References (23)
  • Citations (4)
📖 Papers frequently viewed together
15 Citations
10 Citations
2 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Nghia Nguyen (UCSD: University of California, San Diego)H-Index: 20
#2Huy N. TrinhH-Index: 24
Last. Mindie H. Nguyen (Stanford University)H-Index: 34
view all 10 authors...
Background and Aim Suboptimal viral suppression with adefovir (ADV) poses a challenge in managing chronic hepatitis B. Few studies have evaluated the efficacy of entecavir (ETV) in ADV-experienced patients. Our aim is to assess treatment effectiveness of ETV in ADV-experienced patients. Methods ADV-experienced patients switched to ETV were enrolled from six US clinics. Patients completed a median of 24 months of ETV after switch. Patients were categorized into partial responders (detectable HBV-...
6 CitationsSource
#1Weixia Ke (Guangdong Pharmaceutical University)H-Index: 3
#2Li Liu (Guangdong Pharmaceutical University)H-Index: 11
Last. Yi Yang (Guangdong Pharmaceutical University)H-Index: 7
view all 7 authors...
Objective Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-analysis to discern comparative efficacy and safety. Methods Published data relevant to a comparison of TDF and ETV used in HBV were included. HBV DNA suppression rate, ALT normalization rate, and HBeAg seroconversion rate a...
35 CitationsSource
#2F. ZoulimH-Index: 8
Last. P. MarcellinH-Index: 8
view all 15 authors...
6 CitationsSource
#1Jörg PetersenH-Index: 35
#2Renate HeyneH-Index: 10
Last. Dietrich HueppeH-Index: 12
view all 19 authors...
4 CitationsSource
#1Jeong-Hoon Lee (SNU: Seoul National University)H-Index: 24
#2Yuri Cho (SNU: Seoul National University)H-Index: 14
Last. Yoon Jun Kim (SNU: Seoul National University)H-Index: 37
view all 12 authors...
The efficacy of entecavir (ETV) treatment in chronic hepatitis B (CHB) patients who were exposed to lamivudine (LAM) but had no detectable LAM resistance (LAM-R) is not well evaluated. In this study, we aimed to evaluate whether the probability of developing genotypic resistance to ETV in LAM-exposed patients with or without LAM-R is comparable to that in antiviral-naive patients. This retrospective cohort study included 500 consecutive patients with CHB who started ETV monotherapy at a single t...
21 CitationsSource
We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naive patients with chronic hepatitis B (CHB). The criteria for inclusion were being NA naive or having previous LAM-F and receiving TDF therapy for at least 6 months. Biochemical and virological tests were performed at the baseline, at 3-month intervals in the first year, and every 6 months thereafter. The primary outcome mea...
34 CitationsSource
#1Severine Margeridon-Thermet (Stanford University)H-Index: 6
Last. Robert W. Shafer (Stanford University)H-Index: 70
view all 10 authors...
We sought to determine the prevalence of hepatitis B virus (HBV) lamivudine (LAM)-resistant minority variants in subjects who once received LAM but had discontinued it prior to virus sampling. We performed direct PCR Sanger sequencing and ultradeep pyrosequencing (UDPS) of HBV reverse transcriptase (RT) of plasma viruses from 45 LAM-naive subjects and 46 LAM-experienced subjects who had discontinued LAM a median of 24 months earlier. UDPS was performed to a depth of 3,000 reads per nucleotide. M...
22 CitationsSource
175 Citations
Amac: Kronik hepatit B virus infeksiyonu morbidite ve mortalitenin onemli bir nedenidir. Tenofovir disoproksil fumarat ve entekavir, hepatit B virus infeksiyonu tedavisinde ruhsatl› ilaclard›r. Biz, kronik hepatit B nin tenofovir ve entekavir ile 12 ayl›k tedavi sonuclar›n› de¤erlendirdik ve bu ilaclar›n etkinliklerini karfl›laflt›rd›k. Yontem ve Gerec: Cal›flma kompanse karaci¤er hastal›¤› olan 94 kronik hepatit B hastas›n› icerdi. Entekavir grubu 0.5 mg/gun entekavir alan 29 hastay›, tenofovir...
23 CitationsSource
#1Yun-Fan Liaw (CGU: Chang Gung University)H-Index: 69
#2Jia-Horng (NTU: National Taiwan University)H-Index: 67
Last. Masao Omata (UTokyo: University of Tokyo)H-Index: 121
view all 20 authors...
Large volume of new data on the natural his- tory and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the applica- tion of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV mana...
746 CitationsSource
Cited By4
#1Mindie H. Nguyen (Stanford University)H-Index: 34
#2Hwai I. Yang (AS: Academia Sinica)H-Index: 36
Last. Huy N. TrinhH-Index: 24
view all 10 authors...
6 CitationsSource
#1Bircan Kayaaslan (Yıldırım Beyazıt University)H-Index: 5
#2Esragül AkinciH-Index: 20
Last. Fehmi Tabak (Istanbul University)H-Index: 26
view all 9 authors...
2 CitationsSource
#1Marlone Cunha-Silva (State University of Campinas)H-Index: 1
#2Fábio R.T. Marinho (State University of Campinas)H-Index: 1
Last. Jazon Romilson de Souza Almeida (State University of Campinas)H-Index: 9
view all 7 authors...
Abstract Background Chronic hepatitis B is a major cause of cirrhosis, and the natural history of the disease has several clinical stages that should be thoroughly understood for the implementation of proper treatment. Nonetheless, curing the disease with antiviral treatment remains a challenge. Aims To describe the clinical course, response to treatment, and poor prognostic factors in 247 hepatitis B virus chronic infection patients treated in a tertiary hospital in Brazil. Methods This was a r...
1 CitationsSource
#1Goh Eun Chung (Seoul National University Hospital)H-Index: 17
#2Eun Ju Cho (SNU: Seoul National University)H-Index: 16
Last. Fabien Zoulim (Lyon College)H-Index: 20
view all 12 authors...
5 CitationsSource